Paroxetine 40 mg tablets recalled for out-of-specification impurities
Golden State Medical Supply Inc. is recalling Paroxetine 40 mg tablets due to failed impurity specifications. A total of 5,626 bottles were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II pharmaceutical recall based on quality-control testing rather than reported illnesses or injuries. The out-of-specification impurities represent a precautionary concern, warranting a Moderate-severity classification consistent with voluntary precautionary recalls.
Plain-English summary
Golden State Medical Supply Inc. is recalling Paroxetine 40 mg tablets, USP, due to failed impurity and degradation specifications. The tablets were manufactured by Apotex Inc. in Toronto, Ontario, Canada, and packaged by GSMS Inc. in Camarillo, California.
The recall affects three package sizes: 30-count bottles (NDC 60429-737-30), 90-count bottles (NDC 60429-737-90), and 1,000-count bottles (NDC 60429-737-10). Affected lot numbers include GS036488, GS037091, GS037701, GS037090, GS037702, GS036677, GS037117, and GS037699, all with an expiration date of August 31, 2024.
Out-of-specification results were detected for the excipient Amadori Glucose adduct of Paroxetine, indicating the presence of degradation products beyond acceptable limits. A total of 5,626 bottles were distributed nationwide throughout the United States.
The recalled product
- Product
- PAROXETINE tablets, USP, 40 mg, Packaged as a) 30-count bottle, NDC 60429-737-30; b) 90-count bottle NDC 60429-737-90; c)1000-count bottle, NDC 60429-737-10; Rx Only, Manufactured by Apotex, Inc., Toronto, Ontario, Canada, M9L 1T9, Packaged by GSMS, Incorporated, Camarillo, CA 9
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Psychiatric / SSRI
- Hazard
- impurity
- degradation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot # a) GS036488
- GS037091
- GS037701
- Exp. 08/31/2024
- b) GS037090
- GS037702
- c) GS036677
- GS037117
- GS037699
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27